Biochip Advances Towards Clinical-Ready Device Development
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Archer Materials Limited reports advancements in the development of its Biochip technology towards a clinically-ready potassium testing device, highlighting progress in industrial design and regulatory preparations. The company has successfully integrated haemolysis sensing technology into its Biochip platform, which is crucial for accurate potassium readings in blood tests. Additionally, Archer is expanding its Biochip capabilities to include lithium testing, demonstrating measurement accuracy within clinically relevant ranges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Archer Materials Limited on 6ix
Earlier from Archer Materials
- Archer Materials investor webinar on the IonQ partnership and Share Purchase Plan
- Archer Completes $7m Placement and Launches SPP Offer
- Presentation - Bringing Quantum Computing to Australia
- Archer enters strategic agreement with quantum leader, IonQ
- Archer QML Project achieves key milestones
Later from Archer Materials
- Early Pre-Pilot Study Advances Potassium Biosensor
- Appendix 4E and 2026 Annual Report
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Archer Materials into a list and get an email when it puts out news.
Follow Archer Materials